Be cautious ahead of Canopy Growth Corporation's FQ3 results, as weak financials and low margins may hinder stock performance ...

Shares in Canopy Growth fell sharply Friday morning after the company's loss missed expectations in the fiscal third quarter. Shares fell over 18% to 3.27 Canadian dollars ($2.29).

The Smiths Falls, Ontario-based cannabis company posted a narrowed net loss of 121.9 million Canadian dollars ($85.2 million), or C$1.11 a share, for the three months ended Dec. 31, compared with a ...

Whether this support will actually translate into action when Trump takes office for his second term ... points (see more details here). Canopy Growth Corporation (NASDAQ:CGC), together with ...

Reports Q3 revenue C$74.8M vs. C$78.5M last year. “Canopy Growth’s (CGC) third quarter highlights that our business has the right ingredients ...

Alliance Global Partners analyst Aaron Grey lowered the firm’s price target on Canopy Growth (CGC) to C$4 from C$7 and keeps a Neutral rating ...

Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX: WEED) (NASDAQ: CGC) will release its financial results for the third quarter fiscal year 2025 ended December 31, 2024 before ...

In November 2023, Canopy Growth received a letter from the staff of the SEC, and it subsequently had discussions with the Office of the Chief Accountant of the SEC. There has been no updated ...

Strong holiday sales drove Storz & Bickel net revenue growth of 19% year-over-year Record quarter for Canada medical cannabis with net revenue increasing 16%; international ...

Canopy Growth Q3 sales hit C$74.76 million, surpassing estimates. Medical cannabis revenue rose 16%, while adjusted EBITDA loss improved 61% year-over-year.

Canopy Growth Corporation’s CGC share price has surged by 22.22%, which has investors questioning if this is right time to sell.